REDUCE MRSA: From Novel Idea to 74,000 Patients

Posted on by CDC's Safe Healthcare Blog
John Jernigan, M.D.
John Jernigan, M.D.

Author – John Jernigan, MD, MS
Director of CDC’s Office of Prevention Research and Evaluation and head of CDC’s Prevention Epicenters Program.

I am excited to announce the results of the REDUCE MRSA study which evaluated three current strategies for preventing methicillin-resistant Staphylococcus aureus (or MRSA) among adult critical care patients. This study – one of the largest to date on this subject, including over 74,000 patients — was recently published in the New England Journal of Medicine.   The study shows that using antimicrobial soap and ointment on all intensive-care unit (ICU) patients can reduce bloodstream infections caused by MRSA and other germs by 44 percent. 

The study is important for several reasons.  First, it answers questions about control of antimicrobial resistant organisms and other healthcare-associated infections, and offers a promising new approach to protecting patients and saving lives.  The study is also important because it demonstrates how creating the right partnerships can help us advance the science of patient safety.  This study was made possible through a unique collaborative partnership having its roots in the CDC Prevention Epicenters Program, a group of CDC-funded researchers who work together with CDC scientists to explore novel approaches to save patients from healthcare-associated infections.  Early research from these investigators and others conducted on a very small scale in single hospitals suggested that reducing germs on patient’s skin by bathing with a skin antiseptic would decrease transmission of pathogens and potentially prevent infections. To build on these results and to fill gaps in our knowledge about how best to prevent MRSA infection, CDC continued to partner with its Prevention Epicenter investigators, led by  University of California, Irvine,  and Harvard Pilgrim Health Care Institute, to design the REDUCE MRSA trial. We couldn’t do it alone, however.  The study design required us to partner with a large hospital network that was willing work with us to incorporate scientific method into the everyday delivery of care, essentially becoming a learning healthcare system, and Hospital Corporation of America (HCA)  accepted the invitation to participate. Subsequently, we approached the Agency for Healthcare Research and Quality to provide funds for the study, and our partnership was complete.

The result is a major advance in science, good news for patients, and potentially a model for how to advance the science of patient safety even further.   Taking a novel hypothesis about how to better protect patients, and moving it along a path that began with small scale tests in a single hospital units and led all the way to the bedside of  74,000 patients was a challenging task.  But identifying a novel approach that can reduce bloodstream infections by 44 percent illustrates the journey was well worth it.

The CDC Prevention Epicenters Program continues to work with its partners to move new hypotheses down new paths towards the goal of making patients safer.

Posted on by CDC's Safe Healthcare Blog

7 comments on “REDUCE MRSA: From Novel Idea to 74,000 Patients”

Comments listed below are posted by individuals not associated with CDC, unless otherwise stated. These comments do not represent the official views of CDC, and CDC does not guarantee that any information posted by individuals on this site is correct, and disclaims any liability for any loss or damage resulting from reliance on any such information. Read more about our comment policy ».

    3 yrs ago, I had my right knee replaced. Knowing of hospital Infection possibilities I took Clorox wipes and Lysol too. When I got to my shared room, I wiped down everything, Phone, TV remote and all metal rails and table top. I only stayed 2 days and went home. Well, was a surprised that when I saw my Doctor approximately 4 weeks or so later, I had a boil looking infection approximately 10 inches below my knee. I had not even seen it. After testing I sure enough had MRSA. I was so upset that that had occurred seeing as though I had taken extra precautions. I did not monitor each person (staff) that came in to see if they had washed hands etc. I assumed they had. I am a carrier and never had another infection but it is hard to live with in my mind. After more than a year or so after the Operation, I remembered the other man in my room , I heard a Dr tell him he was referring him to an Infection disease Dr. I had immediately called the floor nurse into my room and told her what I had heard . I also told her I had CLL already and what kind of infection did the man have. She told me, “OH, he had been in for a back Operation but got an infection and had to come back to have it addressed “. I to this day, wonder if he had a Mrsa infection and I got it from him. I guess it doesn’t matter know though. Anyway, just last June of 2015 I had the other knee done, but had my own room. I guess what I want to express is, we have to find a cure for Mrsa and C-diff, and I do not think the medical field is doing their due diligence . I hear that the Medical Pharma’s don’t see enough profit in finding a cure, because other drugs make a lot more profit. Feel free to share this at your June meeting.

    There is a proven protocol that heals MRSA. Two five minute applications one hour apart
    of chlorine dioxide gas. If you use a glass container ,you can actually see it fall into pieces as it heals. The medical profession fails to accept this finding. One can only guess as to why.

    I agree that it is important to consider unintended consequences for any novel intervention. As the authors state in the paper itself, it is possible that widespread use of chlorhexidine and mupirocin could engender resistance, thereby limiting the effectiveness of these agents in the long term. It will therefore be important for surveillance programs to monitor for the emergence of mupirocin and chlorhexidine resistance if this approach is used widely. CDC will carefully weigh these potential concerns against the benefits in the process of determining how the findings of the study might inform CDC infection prevention recommendations.

    There have been concerns expressed among our ID physicians and others about Mupirocin resistance, and whether we are “setting ourselves up” for increasing resistance should the decolonization of ICU patients be adopted on a widespread basis. Please respond to that concern.

    Hello! I send you my thanks for your great contribution to the science, for all your help that you provide worldwide,and special thanks to to all employees of your medical organization CDC for your invaluable contribution, you for your concern! I would very much like to you to be with us and in Ukraine! Regards Max! city ​​of Chernigov, Ukraine

    Environmental contamination of S. aureus as well as Listeria monocytogenes has been a problem with food processing plants for many years. Yes, good GMP controls for handwashing are essential, but we have also found that environmental controls to reduce the niche areas in the facility are important as well. Have used Lactobacillus saki and acidopholus for the elimination of these niche areas in the facility. Yes cleaning is essential, but having the correct microflora in the building assists in these areas especially in areas where the niche exists.

    Very helpful article and research, keep it up guys as we use the research in clean room food environments!

Post a Comment

Your email address will not be published.

All comments posted become a part of the public domain, and users are responsible for their comments. This is a moderated site and your comments will be reviewed before they are posted. Read more about our comment policy »

Page last reviewed: November 18, 2016
Page last updated: November 18, 2016